ClinicalTrials.gg
CompletedNCT04018664Updated May 21, 2025Results posted

Oral Abuse Potential Study of Nalbuphine

A Phase 1 interventional study of Nalbuphine HCl solution and Placebo solution in Nalbuphine and Opioid Abuse, sponsored by Trevi Therapeutics. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Trevi Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled May 2018, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.

Enrollment
15th of 32
56 · median 51
Started
2018
with 2 others
Phase 1
4 of 36
none open now
Registered
15th of 36
by date

Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 1, and was the 15th registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Opioid-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). The amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated.

This study has 2 parts: Part A and Part B.

Read the detailed description

This study will be a single-dose, randomized, double-blind, active- and placebo-controlled, double dummy, 2-part, 7-way crossover study to determine the abuse potential of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution and placebo, in non-dependent, recreational opioid users. The study will be conducted in a single clinical research unit (CRU).

The purpose of Part A is to find the appropriate doses (a low, intermediate, and high dose) of nalbuphine solution to use in Part B. Part A of the study has two visits to the research clinic: a screening visit and dose selection visit. The visits will involve a 2-night stay (3 days total) in the research clinic.

In the Main Study Treatment Phase in Part B, the total estimated duration between each dose of study drug is approximately up to 7 days, of which the subject will spend 3 days/2 nights in the research clinic and approximately up to 4 days at home.

The primary objective of the Main Study is to evaluate the abuse potential of orally administered nalbuphine solution and nalbuphine ER intact tablets relative to hydromorphone solution (the active comparator) and placebo in non-dependent, recreational opioid users.

03

Conditions studied

  • Nalbuphine
  • Opioid Abuse

Keywords

  • nalbuphine
  • abuse potential
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects 18 to 55 years of age
  • Current opioid users who have used opioids for recreational (non-therapeutic) purposes

Exclusion criteria

Exclusion Criteria:

  • Self-reported substance or alcohol dependence (excluding nicotine and caffeine)
  • Heavy smoker (≥ 20 cigarettes per day) and/or who is unable to abstain from smoking for at least 8 hours during the in clinic periods.
  • History or presence of abnormality as assessed by physical examination, medical history, ECGs, vital signs, or laboratory values.
  • History or presence of any clinically significant illness
  • History of major mental illness that may affect the ability of the subject to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo 150 mL flavored beverage

    Drug: Placebo solution

  • Experimental
    90 mg nalbuphine HCl solution

    90 mg nalbuphine HCl solution 9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    120 mg nalbuphine HCl solution

    120 mg nalbuphine HCl solution 12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    150 mg nalbuphine HCl solution

    150 mg nalbuphine HCl solution 15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    180 mg nalbuphine HCl solution

    180 mg nalbuphine HCl solution 18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    270 mg nalbuphine HCl solution

    270 mg nalbuphine HCl solution 27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    Up to 405 mg nalbuphine HCl solution

    Up to 405 mg nalbuphine HCl solution Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage

    Drug: Nalbuphine HCl solution

  • Experimental
    Up to 540 mg nalbuphine HCl solution

    Up to 540 mg nalbuphine HCl solution Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage

    Drug: Nalbuphine HCl solution

Interventions

  • nalbuphine solution administered at various strengths

    Also known as: NAL ER

  • DrugPlacebo solution

    Placebo

06

What researchers measure

Primary outcomes

  1. To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).

    Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max

    Time frame: 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose

07

Results

Posted Aug 31, 2020

Participant flow

Only Part A of this study was completed. Treatment arms summarized are those that were used on in Part A.

Participant flow — Overall Study
MilestonePlacebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl Solution
Started146666666
Completed146666666
Not completed00000000

Outcome measures

PrimaryTo Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).

Only Part A of thie study was conducted because of closure the clinical research unit (CRU) before Part B could be initiated. Summary statistics are provided for C-max

Time frame:
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose
Reported as:
Mean · microgram/L
To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).
microgram/LPlacebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl Solution
To Identify the Appropriate Low, Intermediarte, and High Doses of Nalbuphine Solution (Part A) to be Administered as Single Doses in the Treatment Phase of the Main Study (Part B).—21.70 ± 6.6551.90 ± 26.8968.67 ± 30.1976.60 ± 51.3456.00 ± 6.09158.55 ± 115.65196.83 ± 92.34

Adverse events

Collected over 24 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/14 (0%)0/14 (0%)0/14 (0%)
90 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
120 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
150 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
180 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
270 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
Up to 405 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)
Up to 540 mg Nalbuphine HCl Solution0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
Mean33.4 ± 8.338.5 ± 11.233.2 ± 7.331.0 ± 9.437.3 ± 13.634.8 ± 5.634.3 ± 11.942.5 ± 12.335.3 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
Female033110008
Male14335566648
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
Hispanic or Latino000002103
Not Hispanic or Latino14666645653
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
American Indian or Alaska Native000000000
Asian101100104
Native Hawaiian or Other Pacific Islander000000000
Black or African American201112108
White8544542638
More than one race000000000
Unknown or Not Reported310000206
Region of Enrollment
Region of Enrollment(participants)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
Canada14666666656
BMI
BMI(kg/m**2)Placebo90 mg Nalbuphine HCl Solution120 mg Nalbuphine HCl Solution150 mg Nalbuphine HCl Solution180 mg Nalbuphine HCl Solution270 mg Nalbuphine HCl SolutionUp to 405 mg Nalbuphine HCl SolutionUp to 540 mg Nalbuphine HCl SolutionTotal
Mean26.48 ± 3.4526.17 ± 3.1525.53 ± 4.0423.48 ± 2.5726.18 ± 4.3925.43 ± 3.6224.53 ± 3.1722.32 ± 1.5525.23 ± 3.44
08

Study locations

1 site
  • 001
    Toronto, Ontario M5V 2T3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Dec 2018, 6 months.

Results were first posted in Aug 2020, 1 year 8 months after primary completion.

Of 78 phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2019
First posted
Jul 12, 2019
StartActual
May 29, 2018
Primary completionActual
Dec 3, 2018
CompletionActual
Jun 2, 2020
Results first posted
Aug 31, 2020
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04018664
Lead sponsor
Trevi Therapeutics
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
May 29, 2018
Primary completion
Dec 3, 2018
Completion
Jun 2, 2020
Results posted
Aug 31, 2020
Last update
May 21, 2025

Study contacts

Chief Development Officer
study director · Trevi Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion